Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab with bevacizumab within its marketing authorisation for treating unresectable or advanced hepatocellular carcinoma.
 
Status In progress
Process STA 2018
ID number 1655

Provisional Schedule

Committee meeting 07 October 2020
Expected publication 16 December 2020

Project Team

Project lead Gavin Kenny

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors Roche (Atezolizumab, bevacizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Association of the Study of the Liver
  British Society of Gastroenterology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Bayer (sorafenib)
  Eisai (lenvatinib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
04 June 2020 Invitation to participate
11 December 2019 - 20 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
02 August 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance